Thank you, Rod. Good morning, everyone. Despite what continues to be a challenging macro environment, strong operational and commercial execution has led to robust adjusted gross margin, EPS and EBITDA expansion in the quarter. Strong international results, partially offset by the challenging performance of our Right-to-Play categories in North America led to slight organic sales growth, which was below our expectations. Continued excellent productivity performance and realization of our price and revenue management strategies, once again, unlocked notable gross margin accretion, enabling us to raise our full year adjusted EPS and EBITDA outlook ranges, which I'll discuss shortly. For the quarter, organic net sales growth was largely driven by higher pricing and strategic revenue management actions, while volumes were lower. International organic growth was just under 6%, underpinned by both price and volume gains. As previously mentioned, the external environment is challenging. The dollar remains stubbornly strong while interest rates remain elevated, and importantly, consumption across U.S. categories has slowed. Aggregate consumption across our U.S. segments declined 0.4% in the quarter, a meaningful sequential step down from last quarter's 2% 13-week growth and the 5% trailing 52-week trend as gains from pricing eased compared to a year ago and volumes declined across most categories. The change in trend was most pronounced in Wet Shave and reflective of the drug channel, where we're seeing lower foot traffic, retailer execution challenges, and a highly competitive environment on shelves. Operationally, our teams continue to execute at a high level. The supply chain organization realized better than expected productivity savings, and our commercial teams drove strong gains from both price and revenue management. In total, these efforts combined to provide 430 basis points of gross margin tailwinds in the quarter, which more than offset core inflationary pressures and unfavorable mix. Notably, we delivered 320 basis points of adjusted gross margin accretion, adjusted EPS of $0.88 per share and adjusted EBITDA of $99.7 million, all of which were marked improvements over the previous year and above our expectations. Now let me turn to the detailed results for the quarter. Organic net sales increased 0.1%, as strong performance across international markets, and double-digit global growth in Sun Care and Grooming were offset by declines in North America Wet Shave and FemCare. Strong international performance was driven by price gains of over 3% and volume gains of over 2%, resulting in just under 6% organic growth. Performance in Japan continued to be a highlight, as a return to healthy category consumption was met with price execution and supported by incremental brand investment. Mid-single-digit growth in Europe and high-single-digit growth across LatAm were noteworthy as well. Organic sales in North America were down 2.8%, as double-digit growth in Sun and Grooming was offset by declines in Wet Shave, FemCare, and Skin. North America volumes were down 5.4%, while pricing and revenue management delivered nearly 3 points of growth. Wet Shave organic net sales were down 4.5%, with declines in men than women systems and preps offset by slight growth in disposables. International Wet Shave grew mid-single-digits and from both price and volume gains, reflecting improved market conditions, solid distribution outcomes, and strong in-market brand activation. In North America, organic net sales declined double-digits and were negatively impacted by cycling last year's NPD pipe sale in the club channel. Excluding the impact of the product launch cycling, total Wet Shave sales would have declined just under 2% in the quarter, which was in line with our expectations. In the U.S. razors and blades category, consumption was down 3% in the quarter, driven mostly by the drug channel, with declining traffic, weaker retailer performance, and heightened promotional levels all dampened results. Our market share decreased 80 basis points overall, this was entirely driven by the aforementioned drug channel, where we over-index. Outside of drug, total category consumption was only marginally down, and we gained market share, including share expansion in mass. The Billie brand continued to gain share, delivering 360 basis points of share growth as it continues to scale at retail. In the quarter, the brand reached a 16 share at Walmart and over 10 share at drug. Sun and Skin Care organic net sales increased approximately 12%, as nearly 13% growth in Sun Care and 18% growth in Grooming were partially offset by declines in Skin. North America and international each grew Sun Care over 12%, with both delivering volume and price gains. In the U.S., challenging early season weather was evident in category performance, which was down approximately 4%, and our share declined 190 basis points. Grooming organic net sales increased over 18%, led by over 26% growth in Cremo in the U.S., over 12% growth in Bulldog internationally, and the rollout of Billie's body care launch at retail. Grooming organic growth, excluding the Billie launch, was a robust 11%. Wet Ones' organic net sales declined 11%, and our share declined slightly to approximately 73%. FemCare organic net sales were down 12% for the quarter, and the decline was more than expected. Consumption in the category was up 1.9%, though entirely driven by pads, as tampon consumption was flat and liners declined. The category continues to be impacted by retailer destocking and heightened promotional intensity, and we saw some executional delays in the changeover to the new planogram sets, which was a headwind in the quarter as we deploy our new Carefree master brand. Playtex Sport continued to be a drag with sluggish consumption and share performance. Now moving down the P&L. Gross margin rate on an adjusted basis increased 320 basis points, inclusive of 10 basis points of unfavorable currency. We delivered approximately 240 basis points of productivity savings and realized 190 basis points of price and strategic revenue management gains. This was partially offset by core gross inflationary pressures of about 60 basis points and 40 basis points of negative mix and other items. A&P expenses were 10.5% of net sales and flat to last year. Adjusted SG&A increased 20 basis points in rate of sale versus last year, as higher people-related costs were only partly offset by savings realized from ongoing operational efficiency programs. Adjusted operating income was $80.7 million compared to $63.1 million last year, an increase of approximately 28%. Adjusted operating margin increased 300 basis points, reflecting higher gross margin partially offset by higher A&P and SG&A expenses. GAAP-diluted net earnings per share were $0.72 compared to $0.37 in the second quarter of fiscal '23, and adjusted earnings per share were $0.88 compared to $0.56 in the prior year period. Currency movements had approximately $0.02 per share in unfavorable impact in the quarter as translational currency benefits within operating profit were more than offset by transactional headwinds in operating profit and lower hedge gains within other income and expense. Adjusted EBITDA was $99.7 million, inclusive of a $1.3 million unfavorable currency impact, compared to $83.6 million in the prior year. Net cash provided by operating activities was $56.1 million for the first half, compared to $1.9 million in the prior year period. We ended the quarter with $196 million in cash on hand, access to the $309 million undrawn portion of our credit facility, and a net debt leverage ratio of 3.4x. In the quarter, share repurchases totaled $15 million, and we continued our quarterly dividend payout and declared another cash dividend of $0.15 per share for the second quarter. In total, we returned $23.5 million to shareholders during the quarter. Now turning to our outlook for fiscal 2024, our strong half 1 financial performance, highlighted by accelerated year-over-year gross margin accretion, provides the catalyst for our raising of the full-year outlook for both adjusted EBITDA and EPS. We continue to expect organic net sales growth to be in the range of 2% to 4%, though now anticipate the full-year growth to be at the lower end of our previously provided range. This is largely reflective of 2Q results, as our half 2 organic growth outlook remains mostly in line with our previous expectations, and with a higher growth profile in Q4 than in Q3. We now expect full-year adjusted gross margin accretion of 120 basis points, inclusive of 10 basis points of FX headwinds, and this represents a 40 basis point improvement over our previous outlook. Our outlook for margin expansion in half 2 is largely unchanged, as we expect stronger productivity gains and continued easing of inflation and FX to be offset by increased promotional levels and the negative impact of lower sales on capacity utilization. As mentioned, we're also increasing our outlook for adjusted EPS and EBITDA, essentially flowing through the overperformance from 2Q to the full year, and holding half 2 generally consistent with our previous outlook, as modestly improved FX is offset by the impact of slightly lower sales. Adjusted EBITDA is now expected to be in the range of $348 million to $360 million. Adjusted EPS is now anticipated to be in the range of $2.80 to $3, inclusive of approximately $0.17 per share of currency headwinds. Adjusted earnings per share at the midpoint of the range is now expected to increase approximately 12% or 18% at constant currency. For more information related to our fiscal '24 outlook, I would refer you to the press release that we issued earlier this morning. And now I'd like to turn the call back over to the operator for the Q&A session.